
    
      A prospective, post-marketing observational study was conducted in 50 chronic heart failure
      patients with age 30-70yrs of NYHA Class II and prescribed 5 mg Ivabradine twice daily. Heart
      rate was evaluated through ECG & quality of life was measured by a validated questionnaire
      EuroQol-5 Dimension 3 level version (EQ-5D-3L). Baseline demographic includes age, gender,
      height, weight, Body Mass Index, temperature, blood pressure and respiratory rate were
      recorded and patients were followed at week 4 and week 8. Safety and tolerability was
      assessed by adverse drug reaction (ADR) monitoring. Results were analyzed by statistical
      software SPSS version 20.0.
    
  